['Determine if the initiation of an anticholinergic treatment affects the sexual function in women diagnosed with multiple sclerosis (MS).', "It was a single-centre prospective open label study on 18 women affected by MS, with a clinical overactive bladder syndrome, and examined before and after anticholinergic treatment. Several variables were studied before and after treatment: the total anticholinergic load (Anticholinergic Drug Scale [ADS]), the Female Sexual Function Index, the Urinary Symptom Profile (USP) and functional status (EDSS, MIF). Quantitative variables were analyzed using Student's test.", 'Eighteen women with an average age of 48.3 years old (±10.7 years), average EDSS of 4.6 (±1.5) were examined before and after anticholinergic treatment (solifenacin and trospium). Anticholinergic load at baseline was 0.33 (±0.5) and 3.44 (±0.70) after treatment (P<0.0001). The initiation of an anticholinergic treatment allowed a significant improvement on the subscore OAB USP (10.25±4.3 to 6.22±3 P=0.01). No significant impacts of the anticholinergic load on the Female Sexual Function Index (FSFI) score (18.9±10.8 to 21.2±10.8 P=0.06) and sub-items lubrification (3.6±2.2 to 3.7±2.2 P=0.6), pain (3.6±2.5 to 4.2±2.3 P=0.4), desire (3±1.2 to 3±1.5 P=0.7), orgasm (2.7±2.1 to 3±2.4 P=0.4), satisfaction (3.9± to 4±2 p=0.9), arousal (2.9±2 to 3.3±1.8 P=0.8) was evidenced.'] Do [ Anticholinergics affect the sexual function in women diagnosed with multiple sclerosis ]?